



## II. REPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH (RMNCH)

### II.1 MATERNAL HEALTH

II.1.1 ANTENATAL CONSULTATION	10-14 yrs	15-19 yrs	> 19 yrs
1. Number of pregnant women below 15 years received during the month			
2. Number of pregnant women received for ANC I (1 <sup>st</sup> contact ) during the month			
3. Number of pregnant women who attended their first ANC before 16 weeks			
4. Number of pregnant women received for ANC 4 and above during the month			
5. Number of pregnant women who received the first IPT dose			
6. Number of pregnant women who received the third IPT dose (complete IPT)			
7. Number of pregnant women who received at least two doses of Tetanus vaccine during the current pregnancy during the month			
8. Number of women who received the 1 <sup>st</sup> dose of Tetanus vaccine during the month			
9. Number of women who received the 2 <sup>nd</sup> dose of Tetanus vaccine during the month			
10. Number of women who received the 3 <sup>rd</sup> dose of Tetanus vaccine during the month			
11. Number of women who received the 4 <sup>th</sup> dose of Tetanus vaccine during the month			
12. Number of women who received the 5 <sup>th</sup> dose of Tetanus vaccine during the month			
13. Number of women who received the 1 <sup>st</sup> dose of Tetanus Diphtheria vaccine during the month			
14. Number of women who received the 2 <sup>nd</sup> dose of Tetanus Diphtheria vaccine during the month			
15. Total number of women received for ANC during the month whose blood pressure was measured			
16. Total number of women received for ANC who did the syphilis test			
17. Number of syphilis cases diagnosed in pregnant women in ANC during the month			
18. Number of syphilis cases in pregnant women treated in ANC during the month			
19. Number of pregnant women screened for Hepatitis B during the month			
20. Number of pregnant women who tested positive to Hepatitis B during the month			

II.1.2 DELIVERIES, EMERGENCY OBSTETRIC AND NEONATAL CARE	10-14 yrs	15-19 yrs	> 19 yrs
21. Total number of deliveries in the health facility during the month			
22. Total number of deliveries recorded within the community during the month			
23. Number of women who benefited from AMTSL during the month			
24. Number of deliveries with obstetric complications:			

<i>Number of cases of haemorrhage</i>			
<i>Number of cases of prolonged labour/dystocia</i>			
<i>Number of pre-eclampsia/eclampsia cases</i>			
<i>Number of cases of uterine ruptures</i>			
<i>Number of cases of puerperal infections</i>			
25. Number of caesarean sections performed			
26. Number of obstetric complications cases managed or referred during the month			
27. Number of complicated abortion cases recorded in health facility in the month			
28. Number of maternal deaths recorded in the facility during the month			
29. Number of maternal deaths recorded in the community during the month			
30. Number of maternal deaths audited during the month			
31. Number of abortion-related deaths recorded during the month			
32. Number of women who initiated a family planning method in immediate postpartum during the month			

<b>II.1.3 POST NATAL CONSULTATION</b>	<b>10-14 yrs</b>	<b>15-19 yrs</b>	<b>&gt; 19 yrs</b>
33. Number of women who initiated a family planning method during the post partum period during the month			
34. Number of women who delivered and spent at least 48 hours in the health facility during the month			
35. Number of couples (mother and newborn) who received at least one postnatal consultation within 48 hours following delivery			
36. Number of couples (mother and newborn) who received at least one postnatal consultation between six and ten days following delivery			
37. Number of women who received Vitamin A in postpartum during the month			

<b>II.1.4 BIRTHS</b>	<b>M</b>	<b>F</b>
38. Number of live births recorded in the health facility during the month		
39. Number of live births recorded in the community during the month		
40. Number of birth declarations forwarded to the Civil Status Centre during the month		
41. Number of premature live births recorded during the month		
42. Number of premature or low weight newborns (below 2500g) who were administered kangaroo care		

43. Number of new cases of sick newborns received during the month (fever, jaundice, refusal to breastfeed, lethargy...)	
44. Number of cases of birth asphyxia	
45. Number of cases of birth asphyxia resuscitation (mask and valve)	
46. Number of live births weighing below 2500 g recorded	
47. Number of still births recorded in the health facility	
48. Number of neonatal deaths that occurred during the first 24 hours of life	
49. Number of neonatal deaths (0 to 28 days ) recorded in the HF during the month	

### II.1.5 FAMILY PLANNING

50. Number of new users (additional clients)		
51. Number of users who chose one of the following contraceptive methods during the month	<b>New</b>	<b>Old</b>
<i>Progestin-only pills</i>		
<i>Oestroprogestogenic contraceptive pill</i>		
<i>Morning after pill</i>		
<i>Intramuscular injections (Depo provera,...)</i>		
<i>Subcutaneous injections (Sayana Press)</i>		
<i>Implants</i>		
<i>IUD</i>		
<i>VSC: Voluntary surgical contraception (tubal ligation, vasectomy,...)</i>		
<i>Male condom</i>		
<i>Female condom</i>		
<i>Natural method</i>		

### II.2 SCREENING FOR GENESIC CANCERS AND OBSTETRIC FISTULA

52. Number of women aged between 30 to 49 years screened for cervical cancer	
53. Number of suspected breast cancer cases	
54. Number of confirmed breast cancer cases	
55. Number of breast cancer cases managed	
56. Number of breast cancer cases referred	
57. Number of suspected cervical cancer cases	
58. Number of confirmed cervical cancer cases	
59. Number of cervical cancer cases managed	
60. Number of cervical cancer cases referred	
61. Number of obstetric fistula cases detected	
62. Number of obstetric fistula cases managed	
63. Number of obstetric fistula cases detected and referred	

64. Number of prostate cancer cases detected	
65. Number of prostate cancer cases managed	
66. Number of prostate cancer cases referred	

<b>II.3 PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV</b>	
67. Number of male partners of pregnant women received during the month tested HIV-positive	
68. Number of HIV-positive pregnant women who received Co-trimoxazole prophylaxis during the month	
69. Number of HIV-positive pregnant women who initiated ARV triple therapy on site during the month	
70. Number of HIV-positive pregnant women already on triple therapy at the time of their first ANC visit during the month	
71. Number of HIV-positive pregnant women in whom the search for clinical signs of TB was conducted during the month	
72. Number of pregnant women who performed their first HIV test during the current pregnancy in the labour room during the month	
73. Number of pregnant women who performed their first HIV test during the current pregnancy in the labour room and diagnosed HIV-positive during the month	
74. Number of pregnant women who tested negative during ANC who were retested for HIV in the labour room during the month	
75. Number of pregnant women who tested negative during ANC who were retested and diagnosed HIV-positive in the labour room during the month	
76. Number of pregnant women who tested HIV-positive in the labour room and who initiated ART during the month	
77. Number of women who gave birth in the HF during the month	
78. Number of HIV-positive women who gave birth in the HF during the month	
79. Number of children born to HIV-positive mothers in the HF during the month	
80. Number of children born to HIV-positive mothers who started postpartum Nevirapine prophylaxis within 72 hours during the month	
81. Number of HIV-positive women who gave birth out of the HF and came with their babies within 72 hours following delivery during the month	
82. Number of women who started a family planning method during postpartum during the month	
83. Number of HIV-positive women who started a family planning method during postpartum during the month	
84. Number of children born to HIV-positive received for follow-up consultation between 6 and 10 days after birth during the month	
85. Number of children born to HIV-positive received for follow-up consultation between 6 and 8 weeks after birth during the month	
86. Number of children born to HIV-positive mothers who started Cotrimoxazole from 6 weeks postpartum during the month	
87. Number of children born to HIV-positive mothers screened by PCR between 6 and 8 weeks during the month	
88. Number of children born to HIV-positive mothers diagnosed HIV-positive by PCR between 6 and 8 weeks during the month	

<b>II.3 PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV</b>	
89. Number of children born to HIV-positive mothers screened by PCR between 8 weeks and 9 months during the month	
90. Number of children born to HIV-positive mothers diagnosed HIV-positive by PCR between 8 weeks and 9 months during the month	
91. Number of children born to HIV-positive mothers still on exclusive breastfeeding at 6 months	
92. Number of children born to HIV-positive mothers seen at the 9-month visit during the month	
93. Number of children born to HIV-positive seen at the 9-month visit who are up to date with their vaccination	
94. Number of children born to HIV-positive mothers who tested positive by serology between 9 and 18 months and screened by PCR during the month	
95. Number of children born to HIV-positive mothers who tested positive by serology between 9 and 18 months and confirmed by PCR during the month	
96. Number of children born to HIV-positive mothers confirmed HIV-positive by PCR who initiated ART during the month	

### III. CHILD AND ADOLESCENT HEALTH

<b>III.1 CHILD IMMUNIZATION (EPI) ACTIVITIES/ COMMUNICATION FOR IMMUNIZATION</b>	0 to 11 months Number of sessions		12-59 months Persons sensitized
	Planned	Achieved	
97. Immunization in fixed strategy			
98. Immunization in advanced /mobile strategy			
99. Announcement by a town crier or sensitization with a megaphone			
100. Educational talk in health facilities			
101. Educational talk in the community / associations			
102. Communication in churches			
103. Communication with traditional healers			
104. Search for the lost to follow up (number to be looked for and number found)			

<b>III.2 IMMUNIZATION OF CHILDREN (EPI)</b>	0 to 11 months				12-59 months	Refugees
	Fixed		Advanced/Mobile			
	M	F	M	F		
105. Number of children who received BCG vaccine						
106. Number of children who received HepB0 vaccine						
107. Number of children who received OPV0 vaccine						
108. Number of children who received OPV 1 vaccine						
109. Number of children who received OPV 2 vaccine						
110. Number of children who received OPV 3 vaccine						
111. Number of children who received PVI vaccine						

III.2 IMMUNIZATION OF CHILDREN (EPI)	0 to 11 months				12-59 months	Refugees
	Fixed		Advanced/Mobile			
	M	F	M	F		
I 12. Number of children who received DTP+ HepB1+Hib1 (Penta 1) vaccine						
I 13. Number of children who received DTP+ HepB3+Hib2 (Penta 2) vaccine						
I 14. Number of children who received DTP+ HepB3+Hib3 (Penta 3) vaccine						
I 15. Number of children who received the first dose of the pneumonia vaccine (PCV-13-1)						
I 16. Number of children who received the second dose of the pneumonia vaccine (P PCV-13-2)						
I 17. Number of children who received the third dose of the pneumonia vaccine (PCV-13-3)						
I 18. Number of children who received Rota 1						
I 19. Number of children who received Rota 2						
I 20. Number of children who received the first dose of measles/rubella vaccine						
I 21. Number of children who received the second dose of measles/rubella vaccine						
I 22. Number of children immunized against yellow fever						
I 23. Number of children who received MenA vaccine						
I 24. Number of children who received Vitamin A (6- 11 months)						

III.3 IMMUNIZATION OF ADOLESCENTS (EPI)	Fixed	Advanced/ Mobile	Refugees
I 25. Number of girls aged 9-13 years who received the first dose of HPV vaccine			
I 26. Number of girls aged 9-13 years who received the second dose of HPV vaccine			
I 27. Number of girls aged 9-13 years who received the third dose of HPV vaccine			

III.4 STORAGE OF VACCINES AND WASTE MANAGEMENT	
I 28. Minimum temperature recorded	
I 29. Maximum temperature recorded	
I 30. Number of low temperature detectors (temperature > +2°C)	
I 31. Number of high temperature detectors (temperature > +8°C)	
I 32. Number of safety boxes used	
I 33. Number of safety boxes destroyed	

### III.5 Surveillance of AEFIs (Adverse Events Following Immunization)

Type of AEFI	Number	Antigen	Lot No.	Expiry date
134. Fever > 48 hours				
135. Rash				
136. Adenopathies				
137. Abscess				
138. Anaphylactic shock				
139. Others (list them)				

<b>III.6 INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS</b>	
140. Number of diarrhea cases recorded in children below five years (0 to 59 months)	
141. Number of children from 0 to 59 months who received ORS + Zinc (oral rehydration salts and zinc) against diarrhoea	
142. Number of children from 0 to 59 months with pneumonia	
143. Number of children from 0 to 59 months with pneumonia who received an antibiotic treatment	
144. Number of children who received one dose of Mebendazole during the month	



## IV. DISEASE CONTROL

### IV.1 COMMUNICABLE DISEASE CONTROL

IV.1.1 HIV/AIDS CONTROL	< 1 yr			1 - 4 yrs			5 -9 yrs			10 -14 yrs			15 -19 yrs			20-24 yrs			25-49 yrs			≥50 yrs			OVERALL		
	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T
VOLUNTARY COUNSELING AND TESTING OF HIV AND COMPREHENSIVE MANAGEMENT OF PLWHIV																											
145. Number of old PLWHIV on ART expected during the month																											
146. Total number of old PLWHIV on ART who received treatment during the month																											
147. Total number of new PLWHIV who initiated ART and who received their treatment during the month																											
148. Total number of PLWHIV on ART who received their treatment during the month																											
149. Total number of PLWHIV on first line ART who received their treatment during the month																											
150. Total number of PLWHIV on second line ART who received their treatment during the month																											
151. Total number of PLWHIV who switched from first to second line ART during the month																											
152. Number of PLWHIV who received cotrimoxazole during the month																											
153. Number of PLWHIV in whom the clinical signs of tuberculosis were investigated and documented during the month																											
154. Number of PLWHIV who initiated treatment 12 months before the current month																											
155. Number of PLWHIV who did the CD4 count (medical follow up at 12 months) during the month																											
156. Number of PLWHIV who did the viral load test 12 months after treatment initiation during the month																											

IV.1.2 HIV/AIDS CONTROL	< 1 yr			1 - 4 yrs			5 -9 yrs			10 -14 yrs			15 -19 yrs			20-24 yrs			25-49 yrs			≥50 yrs			OVERALL					
	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T			
157. Number of persons on ART presenting a suppression of the viral load 12 months after treatment initiation during the month																														
158. Number of PLWHIV still on ART 12 months after treatment initiation during the month																														
159. Number of deaths of PLHIV reported during the month																														
160. Number of PLWHIV who did not collect their treatment during the month																														
161. Number of PLWHIV absent during the previous month who were found and for whom treatment was reinitiated																														
162. Occasional assistance (PLWHIV not followed up at the ATC/Management Unit but who came to collect their treatment during the month)																														
163. Number of cases of exposure to blood and other biological fluids (BEA) who received ART																														

### IV.1.3 VOLUNTARY TESTING OF HIV/AIDS

		Number of persons counselled during the month	Number of persons tested during the month	Number of persons who took their results during the month	Number of persons tested positive during the month	Number of persons tested positive referred to the management unit during the month	Number of unspecified results during the month
≤ 9 years	M						
	F						
	Total						
10-14 years	M						
	F						
	Total						
15-19 years	M						
	F						
	Total						
20-24 years	M						
	F						
	Total						
25- 29 years	M						
	F						
	Total						
30-34 years	M						
	F						
	Total						
35-39 years	M						
	F						
	Total						
40-44 years	M						
	F						
	Total						
45-49 years	M						
	F						
	Total						
≥ 50 years	M						
	F						
	Total						
Total	M						
	F						
	Total						

<b>IV.1.4 MALARIA CONTROL</b>	<b>&lt; 5 years</b>	<b>≥ 5 years (PW excluded)</b>	<b>Pregnant women (PW)</b>
I64. Number of Long Lasting Insecticide-treated Nets (LLINs) distributed			
I65. Number of cases suspected for uncomplicated malaria (clinical uncomplicated malaria)			
I66. Number of cases suspected for severe malaria			
I67. Number of Rapid Diagnostic Tests (RDT) done by the health staff			
I68. Number of positive Rapid Diagnostic Tests (RDT)			
I69. Number of thick smears tests done by the health staff			
I70. Number of positive thick smears			
I71. Number of fever cases suspected to be uncomplicated malaria for which a confirmation test was not performed (RDT or thick smear)			
I72. Number of cases suspected to be severe malaria for which a confirmation test was not performed (RDT or thick smear )			
I73. Number of uncomplicated malaria cases with positive RDT			
I74. Number of uncomplicated malaria cases with positive thick smear			
I75. Number of severe malaria cases with positive RDT			
I76. Number of severe malaria cases with positive thick smear			
I77. Number of hospitalizations for severe malaria confirmed with RDT or microscopy			
I78. Number of confirmed uncomplicated malaria cases treated by the health staff with ASAQ combination			
I79. Number of confirmed uncomplicated malaria cases treated by the health staff with ACT other than ASAQ			
I80. Number of confirmed severe malaria cases treated with injectable artesunate			
I81. Number of confirmed severe malaria cases treated with injectable artemether			
I82. Number of confirmed severe malaria cases treated with injectable quinine			
I83. Number of fever cases suspected to be uncomplicated malaria with negative RDT who received antimalarial treatment			
I84. Number of uncomplicated malaria cases who received antimalarial treatment without a confirmation test (RDT or thick smear)			
I85. Number of fever cases reported by community health workers			
I86. Number of Rapid Diagnostic Tests (RDT) done and interpreted by community health workers in fever cases			
I87. Number of uncomplicated malaria cases confirmed with RDT by community health workers (pregnant women excluded)			
I88. Number of confirmed cases of uncomplicated malaria (excluding pregnant women) treated by CHWs based on the national policy (with ASAQ)			
I89. Number of cases referred (severe malaria or negative Rapid Diagnostic Test) to the health facility by community health workers			
I90. Number of persons who died from confirmed malaria			

IV.1.5 TUBERCULOSIS CONTROL	Smear-positive Pulmonary Tuberculosis (PTB+)			Smear-negative Pulmonary Tuberculosis (PTB-)			Extra pulmonary Tuberculosis			TOTAL
	0-4 years	5-14 years	15 years and +	0-4 years	5-14 years	5 years and +	0-4 years	5-14 years	15 years and +	
191. Number of suspected and referred cases										
192. Number of suspected TB cases referred to the laboratory for diagnosis										
193. Number of new cases										
194. Number of relapse cases										
195. Number of retreatment cases										
196. Number of treatment failure										
197. Number of patients cured / Treatment completed										
198. Number of patients lost to follow up										
199. Number of patients transferred										
200. Number of TB patients who did the HIV test (with results available in the logbook)										
201. Number of TB patients tested positive for HIV										
202. Number of HIV positive TB patients on ARVs										
203. Number of HIV positive TB patients on cotrimoxazole										
204. Number of TB patients sent to the laboratory for follow up										
205. Total number drug resistant TB patients										
206. Number of TB-related deaths										
207. Number of health personnel diagnosed with TB+										

## IV.2 NON COMMUNICABLE DISEASE CONTROL

Diseases	New cases	Deaths	Diseases	New cases	Deaths
208. Hypertension			209. Sickle cells		
210. Diabetes			211. Gastric ulcer		
212. Stroke			213. Chronic visual impairment		
214. Asthma			215. Chronic hearing impairment		
216. Epilepsy			217. Traumas		
218. Road accidents			219. Mental disorders		
220. Rhumatisme			221. Oral diseases		
222. Domestic violence			223. Rape		

## IV.3 NEGLECTED TROPICAL DISEASE CONTROL

Diseases	New cases	Deaths	Diseases	New cases	Deaths
224. Onchocerciasis			225. Intestinal Schistosomiasis		
226. Trachoma			227. Urinary Schistosomiasis		
228. Leprosy			229. Guinea worm		
230. Buruli Ulcer			231. Yaws		
232. Human African Trypanosomiasis (HAT)			233. Leishmaniasis		
234. Helminthiasis					

### IV.4 SURVEILLANCE OF VACCINE PREVENTABLE DISEASES (VPD)

		235. Acute Flaccid Paralysis (AFP)	236. Neonatal Tetanus	237. Measles	238. Yellow fever
0-28 days	Cases reported				
	Cases investigated				
	Deaths				
1-11 months	Cases reported				
	Cases investigated				
	Deaths				
12-59 months	Cases reported				
	Cases investigated				
	Deaths				
5-14 years	Cases reported				
	Cases investigated				
	Deaths				

IV.4 SURVEILLANCE OF VACCINE PREVENTABLE DISEASES (VPD)		235. Acute Flaccid Paralysis (AFP)	236. Neonatal Tetanus	237. Measles	238. Yellow fever
15 years and above	Cases reported				
	Cases investigated				
	Deaths				
Immunization status	Vaccinated				
	Unvaccinated				
	Unknown				

IV.5 SURVEILLANCE OF EPIDEMIC-PRONE DISEASES AND OTHER PUBLIC HEALTH EVENTS					
Diseases	New cases	Deaths	Diseases	New cases	Deaths
239. Meningitis			240. Chicken pox		
241. Cholera			242. Genital ulcer (non vesicular)		
243. Typhoid fever			244. Plague		
245. Bloody Diarrhoea			246. Rabies		
247. Dracunculosis			248. SRAS (atypical pneumopathy)		
249. Viral hemorrhagic fevers			250. Flu Syndrome		
251. Viral Hepatitis B			252. Dengue		
253. Viral Hepatitis C			254. Smallpox		
255. Acute Gastroenteritis			256. Urethral discharge		
257. Lymphatic Filariasis			258. Dog bite		
259. Anthrax			260. Snake bite		
261. Chikungunya			262. Other cases of poisoning		

#### IV.6 INTEGRATED MANAGEMENT OF ACUTE MALNUTRITION (IMAM)

Note : Table to be filled only by HF with the status of Ambulatory Nutritional Centre (ANC)

Age group	Total at the beginning of the month	New Admissions			RE-ADMISSION following abandonment (< 2 months)	INTERNAL TRANSFER (from ITNC or another ANC)	Total admissions in the ANC	Transfer INTERNAL TRANSFER (to the ITNC or ANC)	Discharged				Total discharged	Total at month end
		P/T < -3 z-score or PB < 115 mm or PB < 180 mm	CEDEMAS	RELAPSE					CURED	ABANDONMENT	DEATHS	NOT RESPONDING		
6-59 months														
> 59 months														
<b>TOTAL</b>														
								%	%	%	%	%		

Age group	New admissions		
	Girls	Boys	Total
6-59 months			
> 59 months			

Inputs	In stock	In	Out	Balance
ATPE (sachet)				
Amoxicilline				

Admissions errors		
Average duration of stay		



Note: Table to be filled only by HF with the status of Internal Therapeutic Nutritional Centre (ITNC)

Age group	Total at the beginning of the month	New admissions					RE-ADMISSION following Abandonment (< 2 months)	INTERNAL TRANSFER (from CNTI or another ITNC)	Total of admissions in the ITNC	Discharge					Total discharged	Total at month end
		P/T < -3 z-score or PB < 115 mm or PB < 180 mm	CEDEMAS	RELAPSE	TREATMENT SUCCESS	CURED				ABANDONMENT	DEATHS	NOT RESPONDING/ MEDICAL REFERENCES				
< 6 months																
6-59 months																
> 59 months																
<b>TOTAL</b>																
										%	%	%	%	%		

Age group	New admissions		
	Girls	Boys	Total
< 6 months			
6-59 months			
> 59 months			

Inputs	In stock	In	Out	Balance
ATPE (sachet)				
Amoxicilline				
FI 00 (sachet)				
ReSoMal (sachet)				

Admission errors		
Average duration of stay		

## V. HEALTH FACILITY ACTIVITIES

V.1 Consultations / hospitalisations/deaths	Number of cases per age group and gender					
	0 – 59 months		5 years and above (excluding Pregnant women)		Pregnant women	Total
	M	F	M	F		
263. Total number of consultations during the month						
264. Total number of available beds						
265. Total number of hospitalized patients during the month						
266. Total number of hospitalization days during the month						
267. Average duration of hospitalization						
268. Number of patients referred to the next level during the month						
269. Total number of deaths recorded during the month						
270. Number of death declarations forwarded to the Civil Status Centre during the month						

V.2 The ten main reasons for consultation during the month	Number per age group and gender						% total consultations
	0 – 59 months		5 -14 years		15 years and +		
	M	F	M	F	M	F	
1-							
2-							
3-							
4-							
5-							
6-							
7-							
8-							
9-							
10-							

V.3 The 10 main reasons for hospitalization during the month	Number per age group and gender						% total hospitalizations
	0 – 59 months		5 -14 years		15 years and +		
	M	F	M	F	M	F	
1-							
2-							
3-							
4-							
5-							
6-							
7-							
8-							
9-							
10-							

V.4 The 10 mains causes of death during the month	Number of deaths per age group and gender						% total deaths
	0 – 59 months		5 -14 years		15 years and +		
	M	F	M	F	M	F	
1-							
2-							
3-							
4-							
5-							
6-							
7-							
8-							
9-							
10-							

V.I BLOOD TRANSFUSION			
271. Number of blood units sampled/collected		272. Number of blood units transfused	
273. Number of blood units tested according to standards 1		274. Number of blood units served	
275. Number of blood units tested for HIV		276. Number of voluntary/benevolent donors	
277. Number of blood units positive to HIV		278. Number of donors retained	
279. Number of family donors		280. Number of blood units destroyed	
281. Number of blood donors screened for viral hepatitis B (HVB)		282. Number of blood donors diagnosed positive for Hepatitis B (HVB)	
283. Number of blood donors screened for syphilis		284. Number of blood donors diagnosed positive to syphilis	
285. Number of blood donors screened for HIV		286. Number of blood donors diagnosed HIV positive	
287. Number of blood donors co-infected with HIV/HVB		288. Number of HIV positive blood donors referred to a management unit	
289. Number of mobile collection campaigns done during the month		290. Number of units collected in fixed strategy	
291. Number of blood units collected in mobile strategy			

<sup>1</sup> HIV, Hepatitis, Syphilis

## VI. TRACER DRUGS

	Tracer drugs	Stock at the beginning of the month	Quantity received within the month	Quantity used	Momentary assistance/redepl oymnt	Loss	Physical stock available at the end of the month	Number of stockout days	Quantity about to become expired
1.	Nevirapine syrup								
2.	NVP 200 mg + 3TC 150 mg + AZT 300 mg oral form								
3.	Efv 600 mg + 3tc 150 mg + tdf 300 mg oral form								
4.	Injectable Artesunate (Number of ampoules)								
5.	Injectable Artemether (Number of ampoules)								
6.	Artesunate+amodiaquine 100mg/270mg tablet (Number of treatments)								
7.	Artesunate+amodiaquine (25mg/625mg or 50mg/135mg) tablet (Number of treatments)								
8.	Sulfadoxine pyrimethamine 500mg /25 mg oral form (Number of tablets)								
9.	Artemether + lumefantrine 20/120 mg (Number of treatments)								
10.	Iron syrup								
11.	Folic acid + iron (25mg +66 mg) tablet								
12.	Paracetamol 500mg oral form								
13.	Paracetamol 120 mg/5ml syrup flacon 100 ml								
14.	Paracetamol 100 mg oral form (Number of tablets)								
15.	Malaria RDT (Number of tests)								
16.	LLIN								
17.	Oral rehydration salts + zinc oxyde								
18.	Doxycycline 100mg tablet								
19.	Ringer lactate solution 500 cc								
20.	Metronidazole 250 mg tablet								
21.	Metronidazole 125 mg/5ml syrup								
22.	Cotrimoxazole 480 mg tablet								
23.	Cotrimoxazole 240 mg / 5 ml, oral suspension								

24.	Amoxicilline 500mg oral form								
25.	Amoxycilline 250 mg / 5ml, syrup, 60 ml Vial								
26.	Ceftriaxone 1g, injectable ampoule								
27.	Glibenclamide 5mg oral form								
28.	Mebendazole 100 mg / 5 ml syrup								
29.	Aluminium Hydroxyde 500 mg								
30.	Omeprazole 20mg oral form								
31.	Iodized Polyvidone 10%								
32.	Oxytocin 10 ui/ml, injectable								
33.	Dexamethasone 04 mg injectable								
34.	Tetanus serum								
35.	Anti-venom serum								
36.	Diazepam								
37.	Magnesium Sulfate 1.5 g/10 ml injectable								
38.	Atropine 0.25 mg tablet								
39.	Fentanyl 100 mg, tablet								
40.	Furosemid 20 mg, injectable								
41.	Ibuprofene 400 mg tablet								
42.	Rifampicine + INH+Pyrazinamide + Ethambutol								
43.	mixtard human Insuline 100 UI/10ml injectable								
44.	<i>Progestative pill</i>								
45.	<i>Oestro-progestogenic pill</i>								
46.	<i>Morning-after pill</i>								
47.	<i>Intramuscular injectable (Depo provera,...)</i>								
48.	<i>Subcutaneous injectable (Sayana Press)</i>								
49.	<i>Implants</i>								
50.	<i>IUD</i>								
51.	<i>Male condom</i>								
52.	<i>Female condom</i>								

VII. EPI inputs	Stock in the health facility (dose)			Stock lost (dose)			Stock used (dose of open vials)	Number of stock out days
	Stock at the beginning of the month	Stock received during the month	Remaining stock at month end	Bad PCV	Frozen	Expired/ Others		
B.C.G.								
OPV								
Hep B								
DPT-HepB +Hib (Penta)								
PNEUMO (PCV 13)								
Rota								
VPI								
RR								
VAA								
MenA								
V.A.T.								
Td								
VPH								
Vit_A 50 000 U.I.								
Vit_A 100 000 U.I.								
Vit_A 200 000 U.I.								
Syringe AB 0.05 ml BCG								
Syringe AB 0,5 ml								
Syringe Dil. 2 ml								
Syringe Dil. 5 ml								
Routine immunization card								
Safety box								

VIII. PHARMACO VIGILANCE	
292. Number of side effects reported during the month	
293. Number of serious side effects reported during the month	
294. Number of serious side effects reported and investigated during the month	

#### IX. COMMUNITY INVOLVEMENT

295. Number of health committee meetings held during the month	
296. Number of management committee meetings held during the month	

## X. HUMAN RESOURCES

Type of staff	Number of staff posted at the HF	Staff available	Retired staff still working
Administrative assistant			
Community Health Worker			
Nursing Aid			
Social worker			
Health Technician			
Laundry staff/ tailor			
Driver			
Dental surgeon/ or Health technician in Dentistry			
Accountant/ superintendent/Cashier			
Warder/Security ward			
State Registered Nurse (IDE) general practitioner			
State Registered Nurse (IDE) specialised			
SRN in Anesthetics			
Senior Nurse			
General practitioner			
Gynecologist Obstetrician			
Pediatrician			
Nephrologist			
Surgeon			
General practitioner			
Administrative staff			
SRN in Midwifery			
Administrative secretary			
Cleaner			
Sanitary technician			
Technician in biomedical maintenance			
Health technician in medical analyses			
Health technician in Physiotherapy			
Health technician in Pharmacy			
Health technician in Radiology, Medical imaging			
Thanatopractor (mortuary attendant)			
Other			

